First Turn Management LLC Has $25.45 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

First Turn Management LLC boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 23.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,581 shares of the biotechnology company's stock after purchasing an additional 34,994 shares during the quarter. Ascendis Pharma A/S makes up approximately 4.1% of First Turn Management LLC's holdings, making the stock its 4th largest position. First Turn Management LLC owned approximately 0.32% of Ascendis Pharma A/S worth $25,446,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter valued at $36,000. GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 102 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after buying an additional 91 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after buying an additional 332 shares during the period.

Analyst Upgrades and Downgrades

ASND has been the topic of several analyst reports. Bank of America raised their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a "buy" rating in a research note on Tuesday, August 13th. Morgan Stanley upped their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an "equal weight" rating in a report on Thursday, May 16th. Oppenheimer upgraded shares of Ascendis Pharma A/S from a "market perform" rating to an "outperform" rating and set a $180.00 price target on the stock in a research report on Thursday, September 5th. Finally, Citigroup decreased their price objective on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $187.08.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $5.41 during midday trading on Friday, reaching $119.22. The company had a trading volume of 575,930 shares, compared to its average volume of 412,822. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The company has a fifty day simple moving average of $132.45 and a two-hundred day simple moving average of $136.73. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -12.41 and a beta of 0.63.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.